Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Basit Öğe Kaydı
dc.authoridGonullu, Emel/0000-0002-6990-4206
dc.authoridKanıtez, Nilüfer Alpay/0000-0003-1185-5816
dc.authoridkucuksahin, orhan/0000-0003-4530-2304
dc.authoridcolak, seda/0000-0002-5703-6739
dc.authoridBilgin, Emre/0000-0002-2260-4660
dc.authoridKaradag, Omer/0000-0002-3443-3117
dc.authoridAkar, Servet/0000-0002-3734-1242
dc.authorwosidYağız, Burcu/JQW-5031-2023
dc.authorwosidGonullu, Emel/AAK-7851-2021
dc.authorwosidKanıtez, Nilüfer Alpay/W-7332-2019
dc.authorwosidkucuksahin, orhan/GZA-3287-2022
dc.authorwosidpehlivan, yavuz/AAG-8227-2021
dc.authorwosidcolak, seda/AAZ-5845-2021
dc.authorwosidBilgin, Emre/C-8092-2015
dc.contributor.authorKalyoncu, Umut
dc.contributor.authorPehlivan, Yavuz
dc.contributor.authorAkar, Servet
dc.contributor.authorKasifoglu, Timucin
dc.contributor.authorKimyon, Gezmis
dc.contributor.authorKaradag, Omer
dc.contributor.authorDalkilic, Ediz
dc.date.accessioned2024-06-12T10:58:42Z
dc.date.available2024-06-12T10:58:42Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients' data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.en_US
dc.description.sponsorshipHacettepe Rheumatology Societyen_US
dc.description.sponsorshipUK received honorary from Abbvie, Amgen, Johnson and Johnson, MSD, Novartis, Pfizer, Roche, UCB. YP received honorary from Abbvie, Roche, Novartis, MSD, Pfizer. SA received honorary from Abbvie, Amgen, MSD, Novartis, Pfizer, Roche, UCB. TK received honorary from Abbvie, Amgen, MSD, Novartis, Pfizer, Roche, UCB. GK received honorary from Abbvie, Amgen, Novartis, Pfizer, UCB. OK received honorary from Amgen, Johnson and Johnson, MSD, Novartis, Pfizer, Roche, UCB. ED received honorary from Abbvie, Amgen, Johnson and Johnson, MSD, Novartis, Pfizer, Roche, UCB. IE received honorary from Abbvie, Amgen, Johnson and Johnson, MSD, Novartis, Pfizer, Roche, UCB. LK received honorary from Abbvie, Amgen, MSD, Novartis, Pfizer, Roche, UCB. DE received honorary from Abbvie, Amgen, MSD, Novartis, Pfizer, UCB. CB received honorary from Abbvie, Amgen, MSD, Novartis, Pfizer, Roche, UCB. HE received honorary from Novartis, Roche. RM received honorary from Abbvie, Amgen, MSD, Novartis, Pfizer, Roche, UCB. NK received honorary from Novartis, UCB. MC received honorary from Abbvie, Amgen, MSD, Novartis, Pfizer, Roche, UCB. SSK received honorary from Abbvie, MSD, Novartis, Pfizer, Roche, UCB. OK received honorary from Amgen, Johnson and Johnson, MSD, Novartis, Pfizer, Roche, UCB. SK received honorary from Abbvie, Amgen, Johnson and Johnson, MSD, Novartis, Pfizer, Roche, UCB. Other authors declare no conflict of interest. This study was funded by Hacettepe Rheumatology Society.en_US
dc.identifier.doi10.3906/sag-2012-5
dc.identifier.endpage1623en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue4en_US
dc.identifier.pmid33611869en_US
dc.identifier.scopus2-s2.0-85114289836en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1615en_US
dc.identifier.trdizinid479713en_US
dc.identifier.urihttps://doi.org/10.3906/sag-2012-5
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/479713
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20166
dc.identifier.volume51en_US
dc.identifier.wosWOS:000691544700002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectBiologic Dmardsen_US
dc.subjectRheumatoid Arthritisen_US
dc.subjectSpondyloarthritisen_US
dc.subjectSociety Classification Criteriaen_US
dc.subjectSpondyloarthritisen_US
dc.titlePreferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemicen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu